Prothrombotic and hemorrhagic effects of aspirin

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 5, 2009, Pages 523-528

  Aguejouf, Omar ^a   Eizayaga, Francisco ^b   Desplat, Vanessa ^a   Belon, Philippe ^c   Doutremepuich, Christian ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b DEPARTAMENTO DE CIENCIAS NATURALES Y ANTROPOLOGÍA   (Argentina)

^c Laboratoires BOIRON   (France)

Author keywords

Aspirin withdrawal; COX 1 inhibition; COX 2 inhibition; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; SALICYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; IN VIVO STUDY; LASER; LOW DRUG DOSE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; THROMBOSIS;

EID: 70449630117     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608319945     Document Type: Article

References (20)

1. Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 ; 366: 1607-1621.
2. Bhatt DL, Fox KA, Hacke W., et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 ; 354: 1706-1717.
3. Sibon I., Orgogozo JM Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004 ; 62: 1187-1189.
4. Maulaz AB, Bezerra DC, Michel P., Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005 ; 62: 1217-1220.
5. Armstrong MJ, Schneck MJ, Biller J. Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients. Neurol Clin. 2006 ; 24: 607-630.
6. Fischer LM, Schlienger RG, Matter CM, Jick H., Meier CR Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med. 2004 ; 164: 2472-2476.
7. Ferrari E., Benhamou M., Cerboni P., Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005 ; 45: 456-459.
8. Burger W., Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention- cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005 ; 257: 399-414.
9. Collet JP, Montalescot G., Blanchet B., et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004 ; 110: 2361-2367.
10. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006 ; 166: 1842-1847.
11. Biondi-Zoccai GG, Lotrionte M., Agostoni P., et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006 ; 27: 2667-2674.
12. Collet JP, Himbet F., Steg PG Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol. 2000 ; 76: 257-258.
13. Albaladejo P., Geeraerts T., Francis F., Castier Y., Leseche G., Marty J. Aspirin withdrawal and acute lower limb ischemia. Anesth Analg. 2004 ; 99: 440-443.
14. Vial JH, McLeod LJ, Roberts MS Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res. 1991 ; 21A: 157-160.
15. Vesvres MH, Doutremepuich F., Lalanne MC, Doutremepuich C. Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation. Haemostasis. 1993 ; 23: 8-12.
16. Doutremepuich C., Aguejouf O., Belon P. Effects of ultra-low-dose aspirin on embolization in a model of laser-induced thrombus formation. Semin Thromb Hemost. 1996 ; 22 (suppl 1). 67-70. (Pubitemid 26268426)
17. Aguejouf O., Belougne-Malfatti E., Doutremepuich F., Belon P., Doutremepuich C. Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res. 1998 ; 89: 123-127.
18. Martínez-GonzÁlez J., Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des. 2007 ; 13: 2215-2227.
19. Aguejouf O., Eizayaga F., Desplat V., Doutremepuich C. Reverse effect of aspirin: is the prothrombotic affect of Aspirin discontinuation mediated by COX 2 inhibition ? Pathophysiol Haemost Thromb. 2007 ; 36: 40-44.
20. Wu KK Control of COX-2 and iNOS gene expressions by aspirin and salicylate. Thromb Res. 2003 ; 110: 273-236.